



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Polygenic Risk for Schizophrenia, Brain Structure, and Environmental Risk in UK Biobank

Citation for published version:

Zhu, X, Ward, J, Cullen, B, Lyall, DM, Strawbridge, RJ, Smith, DJ & Lyall, LM 2021, 'Polygenic Risk for Schizophrenia, Brain Structure, and Environmental Risk in UK Biobank', *Schizophrenia Bulletin Open*, vol. 2, no. 1. <https://doi.org/10.1093/schizbullopen/sgab042>

Digital Object Identifier (DOI):

[10.1093/schizbullopen/sgab042](https://doi.org/10.1093/schizbullopen/sgab042)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Schizophrenia Bulletin Open

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Polygenic Risk for Schizophrenia, Brain Structure, and Environmental Risk in UK Biobank

Xingxing Zhu^{*1}, Joey Ward¹, Breda Cullen¹, Donald M. Lyall¹, Rona J. Strawbridge^{1,2,3}, Daniel J. Smith^{1,4}, and Laura M. Lyall¹

¹Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK; ²Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; ³Health Data Research (HDR), Glasgow, UK; ⁴Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

*To whom correspondence should be addressed; 1 Lilybank Gardens, Glasgow G12 8RZ, UK, Phone: +44 0772 082 4235, e-mail: 2487460Z@student.gla.ac.uk

Schizophrenia is a heritable neurodevelopmental disorder characterized by neuroanatomical changes in the brain, but exactly how increased genetic burden for schizophrenia influences brain structure is unknown. Similarly, how environmental risk factors for schizophrenia impact brain structure is not fully understood. Here we investigated how genetic burden for schizophrenia (indexed by a polygenic risk score, PRS-SCZ) was associated with cortical thickness (CT), surface area (SA), cortical volume (CV), and subcortical structures within 18088 White British ancestry participants with derived brain phenotypes from UK Biobank. We also explored whether environmental risk factors for schizophrenia (childhood trauma, cannabis use, birth weight, season of birth, and Townsend social deprivation index) exacerbated the impact of PRS-SCZ on brain structure. We found that PRS-SCZ was associated with lower CT in the frontal lobe, insula lobe, lateral orbitofrontal cortex, medial orbitofrontal cortex, posterior cingulate cortex, and inferior frontal cortex, and reduced SA and CV in the supramarginal and superior temporal cortex, but not with subcortical volumes. When models included environmental risk factors as covariates, PRS-SCZ was only associated with lower SA/CV within the supramarginal cortex, superior temporal cortex, and inferior frontal cortex. Moreover, no interactions were observed between PRS-SCZ and each of the environmental risk factors on brain structure. Overall, we identified brain structural correlates of PRS-SCZ predominantly within frontal and temporal regions and some of these associations were independent of environmental risk factors, suggesting that they may represent vulnerable biomarkers of genetic risk for schizophrenia. Future research is warranted to establish these associations beyond older White British individuals.

Key words: schizophrenia/polygenic risk/environmental risk/cortical thickness/surface area/cortical volume

Introduction

Schizophrenia is a debilitating and complex psychiatric disorder, affecting about 1% of the population.¹ It is a heritable neurodevelopmental condition that arises via a complex interaction of genetic and environmental risk factors.² Neuroimaging studies have reported brain structural alterations in cortical and subcortical regions in people with schizophrenia relative to healthy individuals.³⁻⁶ These brain changes could be driven by genetic factors and may mediate the effect of genetic risk on the phenotype of schizophrenia.⁷⁻⁹ Genome-wide association studies (GWAS) have identified hundreds of significant loci and indicate a polygenic architecture of schizophrenia.^{8,10,11} A polygenic risk score for schizophrenia, which captures the cumulative effect of significant risk loci across the whole genome, is useful in exploring the neurobiology of schizophrenia.¹²⁻¹⁴ To date, little is known about how polygenic risk for schizophrenia influences brain structure, or how environmental risk factors may influence these associations.

Convergent evidence has demonstrated widespread gray matter reductions in individuals with schizophrenia, including lower cortical volume (CV), reduced cortical thickness (CT), and smaller surface area (SA) and subcortical volumes, predominantly in the frontal and temporal regions.^{3,15-17} Longitudinal neuroimaging studies have demonstrated progressive gray matter changes related to schizophrenia¹⁸⁻²⁰ as well as morphological differences that may be present prior to the onset of symptoms.^{20,21}

High-risk familial studies have also observed brain structural differences in unaffected relatives of patients with schizophrenia relative to controls, suggesting a genetic contribution.^{22–24} The association between polygenic risk scores for schizophrenia (PRS-SCZ) and brain structure has been the subject of some early investigations. Initial work focused on total brain volume, total gray/white matter volume, lateral ventricular volume, and subcortical volumes,^{25,26} and a systematic review of seven studies found inconsistent findings plus a lack of significant associations.²⁷ Recent studies with larger samples reported negative associations with volume in the pallidum, thalamus, and hippocampus, as well as positive associations with the caudate and putamen.^{13,28} Studies on cortical measures have reported negative associations between PRS-SCZ and global CT and insular lobe CT¹², frontal and temporal cortex CT⁵, rostral anterior cingulate cortex CT²⁹ within the general population, as well as global cortical thinning in patients with schizophrenia and bipolar disorder.³⁰ Stauffer et al.²⁸ investigated both micro- and macro-structural MRI metrics, and found colocalization of polygenic risk effects was in frontal cortex, insular, medial and lateral temporal cortex, and ventral visual stream. Relatively few studies have systematically examined associations between PRS-SCZ and regional CT, SA, and CV.^{5,12,29} In addition, almost all published studies in this area have not taken account of the possible influence of environmental risk factors for schizophrenia on brain structure.^{5,12,28,29,31}

Environmental risk factors, along with their interaction with genetic risk, contribute to the occurrence and development of schizophrenia.^{2,32,33} Epidemiological studies have identified multiple risk factors for psychotic disorders, of which childhood trauma, cannabis use, low socioeconomic status, obstetric complications, winter/spring season of birth, and non-right handedness play important roles.^{34–39} In addition, previous studies have found significant interactions between PRS-SCZ and cannabis use, childhood trauma⁴⁰ and birth weight,⁴¹ but not for winter birth,⁴⁰ despite inconsistent results being reported.^{42,43} Furthermore, environmental risk factors may contribute, at least in part, to some of the brain structural abnormalities observed in schizophrenia^{30,44,45} and may also contribute to gene-environment interactions.^{45,46} Habetts et al.⁴⁶ reported stronger reductions of CT for exposure to trauma and cannabis in patients with schizophrenia (vs. healthy controls/siblings); Cancel et al.⁴⁷ found greater reduction of total grey matter in patients who had been exposed to emotional neglect; French et al.⁴⁵ observed more longitudinal reduction in mean CT in adolescents who had ever used cannabis (vs. never used). These studies support the idea that there may be interactions between genetic risk for schizophrenia and environmental risk in contributing to brain abnormalities related to schizophrenia.

Here we investigate associations between PRS-SCZ and cortical metrics (CV, SA, and CT), as well as subcortical

volumes, using data from ~18 000 White British ancestry individuals from UK Biobank. We also assess the impact of environmental risk factors (childhood trauma, cannabis use, birth weight, winter/spring season of birth, and Townsend social deprivation index) on any observed associations between PRS-SCZ and these environmental risk factors. We hypothesized that a higher PRS-SCZ would be associated with lower global CT, thinner frontal and temporal cortices, thinner insula lobe, smaller thalamus, pallidum, and hippocampus.^{5,28,48,49} In addition, we expected that environmental risk factors would influence the associations between PRS-SCZ and related brain structural differences.

Methods

Participants

This study was conducted using participants from UK Biobank under approval from the NHS National Research Ethics Service (UK Biobank-approved applications #6553 and #17689). Freesurfer data (released by Jan 2020) based on the Desikan-Killiany cortical atlas⁵⁰ were available for a total of 21 915 participants. Participants were then excluded for the following reasons: having a developmental or neurological disorder (See [Supplementary Table S1](#) for detailed participant exclusion criteria); self-reported schizophrenia; having withdrawn from the UK Biobank project; non-White British ancestry based on self-report and genetic data; genetic data failing to pass quality control and having an intracranial volume or a PRS-SCZ beyond three standard deviations from the sample mean.

Derivation of the Polygenic Risk Score for Schizophrenia

LDpred was utilized to calculate the PRS-SCZ,⁵¹ based on the summary statistics from a recent GWAS specific to schizophrenia,¹⁰ which included 33 426 schizophrenia patients and 54 065 controls, excluding individuals from UK Biobank. Participants were excluded if over 10% of genetic data was missing; if self-reported sex did not match genetic sex; if purported sex chromosome aneuploidy was reported; if heterozygosity value was a clear outlier and if the PRS-SCZ was beyond three standard deviations from the sample mean. Finally, a total of 18 088 participants were included in this study.

Brain Imaging Variables

All neuroimaging data were acquired, pre-processed, quality controlled, and made available by UK Biobank (https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/brain_mri.pdf). Details on the acquisition parameters and the imaging protocol are documented online and are described within the protocol paper.⁵² Derived phenotypes were used in this study. The main neuroimaging data

consisted of global, lobar, and regional values for CT, SA, and CV of 33 regions (data of temporal pole are not available) in each hemisphere from the Desikan-Killiany cortical atlas.⁵⁰ Global and lobar values were calculated as per Neilson et al.¹² In addition, we analyzed subcortical volumes including thalamus, caudate, putamen, pallidum, hippocampus, amygdala, accumbens processed by subcortical volumetric segmentation in Freesurfer. A more detailed description of these variables is provided within [Supplementary Material](#).

Environmental Risk Factors

Childhood trauma was assessed using the five-item Childhood Trauma Screener developed by Glaesmer et al.⁵³ These questions cover the self-reported frequency of feeling loved, being physically abused, feeling hated, being sexually molested, and being taken to the doctor when needed as a child (data field 20487 to 20491). Participants answered these questions by selecting “Prefer not to answer,” “Never true,” “Rarely true,” “Sometimes true,” “Often,” or “Very often true” ([Supplementary Material](#)).

Cannabis use (<https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=20453>) was reported via an online question, “Have you taken CANNABIS (marijuana, grass, hash, ganja, blow, draw, skunk, weed, spliff, dope), even if it was a long time ago?” Participants chose from “Prefer not to answer,” “No,” “Yes, 1–2 times,” “Yes, 3–10 times,” “Yes, 11–100 times,” and “Yes, more than 100 times.”

Birth weight (<https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=20022>) was reported by participants during a verbal interview. To maximize the number of participants included in analyses, missing values at the initial assessment visit were replaced by those at the first repeat assessment visit or the imaging visit.

Winter/spring season of birth in Northern hemisphere (December to May) was obtained from the month of birth in baseline population characteristics (<https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=52>).

The Townsend deprivation index (<https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=189>) is based on post-code reported at baseline assessment in UK Biobank. A greater Townsend index score implies a higher level of neighborhood social and economic deprivation.

Statistical Analysis

All analyses were carried out using Stata/MP 15.0. For associations between PRS-SCZ and brain structure, PRS-SCZ was set as the independent variable; each brain structural measure was set as an outcome. PRS-SCZ \times hemisphere interactions were examined in a repeated measures format to determine whether analysis of left and right homologous structures separately was required, with sex, age, age,² hemisphere, ICV, scanner positions on the x, y, and z axes, genotype array and

the first fifteen genetic principal components included as covariates. For brain measures that did not show PRS-SCZ \times hemisphere interaction, we repeated the linear mixed model with hemisphere as a fixed effect and included the same covariates as in analyses testing for interaction effects. If there was a significant interaction, analyses on both lateralized structures would be conducted separately. PRS-SCZ and each brain outcome were rescaled into zero mean and unitary standard deviation. Participants with each brain outcome beyond three standard deviations were excluded. False Discovery Rate (FDR) correction,⁵⁴ with a significance threshold of $P < .05$, was applied for each metric individually, by correcting over all eight possible lobar structures, twenty-six parcellations, or seven subcortical volumes, using “p.adjust” function in R.

Furthermore, considering the potential impact of environmental risk factors, we investigated whether associations between PRS-SCZ and brain measures were significant when childhood trauma, cannabis use, birth weight, season of birth, and Townsend deprivation index were included as additional covariates. In total, 8667 individuals had complete data for all five environmental factors. Because the subsample was much smaller compared to that in the main analyses, we wished to clarify whether the reduction in sample size influenced the results. Therefore, we repeated previous analyses in this subsample ($N = 8667$) without controlling for environmental risk factors. For further examination of the influence of environmental risk factors on the relationship between PRS-SCZ and brain structure, we excluded 21 individuals who had used antipsychotic medication (self-report at the imaging visit), considering that antipsychotic medication may also influence brain structure.^{55,56}

We also examined the interaction between PRS-SCZ and each of the environmental risk factors on brain structure. The interaction term, together with main effects of the PRS-SCZ and the environmental risk factor were included in the model, as well as the same covariates in the analysis for PRS-SCZ and brain structure. Multiple comparisons correction for interaction effects was done using FDR correction ($P < .05$) in the same way.

Results

Demographics

A total of 18,088 participants (ages 45–80 years, 8650 males) were included in the analysis. Characteristics of the participants are provided in [Table 1](#). There was no significant sex difference in PRS-SCZ (female = -0.52 , male = -0.52 , $t = 0.955$, $P = .340$), but the differences in birth weight (female = 3.28 kg, male = 3.46 kg, $t = -16.519$, $P < .001$), childhood trauma (female = 1.79, male = 1.55, $t = 6.067$, $P < .001$) and cannabis use (female = 0.33, male = 0.49, $t = -10.152$, $P < .001$) were significant.

Table 1. Descriptive Statistics for Demographic Variables ($N = 18\,088$)

Measure	N (%) or Mean \pm SD (range)
Gender	Male: 8621 (47.66%)
Age (Years)	62.78 \pm 7.46 (45–80)
Polygenic Risk Score	–0.520 \pm 0.152 (–0.985 to –0.057)
Self-Reported Mental Health Status	Depression/postnatal depression: 1513 (8.36%) Mania/bipolar disorder/manic depression: 38 (0.21%) Other mental disorders: 388 (2.15%)
Winter/Spring Season of Birth	Yes: 9201 (50.87%)
Townsend Deprivation Index at Recruitment ($N = 18\,071$)	–2.11 \pm 2.57 (–6.26 to 9.16)
Birth Weight (Kg; $N = 11\,921$)	3.36 \pm 0.61 (0.74–6.78)
Childhood Trauma ($N = 13\,001$)	1.68 \pm 2.32 (0–20)
Antipsychotic Medication ($N = 17\,176$)	No: 17138 (99.78%) Yes: 38 (0.22%)
Cannabis Use ($N = 13\,253$)	No: 10 520 (79.38%) Yes, 1–2 times: 1227 (9.26%) Yes, 3–10 times: 716 (5.40%) Yes, 11–100 times: 497 (3.75%) Yes, more than 100 times: 293 (2.21%)

Note: Other mental disorders: post-traumatic stress disorder, anorexia/bulimia/other eating disorder, obsessive compulsive disorder, anxiety/panic attacks.

Table 2. The Association Between Polygenic Risk Score for Schizophrenia and Brain Structures

Brain Structure	N	β	SE	z	P	$P_{corrected}$	R^2
Lobes							
Cortical Thickness							
Frontal Lobe	18 035	–0.018	0.007	–2.75	.006	.050	0.006
Insula Lobe	18 085	–0.016	0.006	–2.59	.010	.050	0.010
Parcellations							
Cortical Thickness							
Lateral Orbitofrontal	18 071	–0.025	0.007	–3.83	<.001	<.001	0.018
Medial Orbitofrontal	18 073	–0.019	0.006	–3.03	.002	.013	0.013
Posterior Cingulate	18 084	–0.021	0.006	–3.46	.001	.009	0.020
Inferior Frontal	18 037	–0.026	0.006	–4.09	<.001	<.001	0.015
Surface Area							
Supramarginal	18 072	–0.016	0.005	–3.15	.002	.026	0.017
Superior Temporal	18 073	–0.015	0.005	–3.16	.002	.026	0.012
Cortical Volume							
Supramarginal	18 073	–0.016	0.005	–3.19	.001	.013	0.017
Superior Temporal	18 061	–0.018	0.005	–3.59	<.001	<.001	0.015

Note: SE, standard error; R^2 , estimate of variance explained by PRS in %.

Associations Between PRS-SCZ and Cortical Thickness

We found a significant interaction between PRS-SCZ and hemisphere on the CT in the occipital lobe (Supplementary Table S2), thus analyses on the CT in the left and right occipital lobes were additionally performed. There was no significant association between PRS-SCZ and global CT ($\beta = -0.012$, $P_{corrected} = .237$; Table 2 shows significant associations only; Supplementary Table S3 lists all the results). In the eight lobar structures, CT in the frontal lobe ($\beta = -0.018$, $P_{corrected} = .050$, $R^2 = 0.006\%$; Table 2) and insula lobe ($\beta = -0.016$, $P_{corrected} = .050$, $R^2 = 0.010\%$) were associated with PRS-SCZ. Moreover,

we found a higher PRS-SCZ was associated with reduced CT in the lateral orbitofrontal cortex ($\beta = -0.025$, $P_{corrected} < .001$, $R^2 = 0.018\%$), the medial orbitofrontal cortex ($\beta = -0.019$, $P_{corrected} = .013$, $R^2 = 0.013\%$), the posterior cingulate cortex ($\beta = -0.021$, $P_{corrected} = .009$, $R^2 = 0.020\%$) and the inferior frontal cortex ($\beta = -0.026$, $P_{corrected} < .001$, $R^2 = 0.015\%$). Figure 1A illustrates the associations between PRS-SCZ and regional CT. In the analyses excluding participants with mental disorders, the results were equivalent (Supplementary Table S4).

In the subsample with complete data on environmental risk factors (childhood trauma, cannabis use, birth weight, winter/spring season of birth, and Townsend deprivation

index), PRS-SCZ was modestly associated with thinner CT in the above regions (Supplementary Table S5), although none of these associations were significant after FDR correction in this smaller sample. Similarly, after controlling for the environmental risk factors and excluding participants who had used antipsychotic medication, there were no significant associations, although a similar negative pattern of association was found (Table 3 shows significant associations only; Supplementary Table S6 lists all the results; Supplementary Figure S1).

Associations Between PRS-SCZ and Surface Area

No interactions were observed between PRS-SCZ and hemisphere for global or regional SA (Supplementary Table S2). Although PRS-SCZ was not associated with global SA ($\beta = -0.002$, $P_{corrected} = .665$; Supplementary Table S3; Figure 1B), we found an association with reduced SA in the supramarginal cortex ($\beta = -0.016$, $P_{corrected} = .026$, $R^2 = 0.017\%$; Table 2) and the superior temporal cortex ($\beta = -0.015$, $P_{corrected} = .026$, $R^2 = 0.012\%$). In the analyses including healthy participants only, we found the same results (Supplementary Table S4). Analyses in the subsample also found significant associations with

these two regions, in addition to inferior frontal cortex (Supplementary Table S5).

When these analyses were adjusted for environmental factors, the associations with supramarginal cortex ($\beta = -0.028$, $P_{corrected} < .001$; Table 3), superior temporal cortex ($\beta = -0.021$, $P_{corrected} = .026$) and inferior frontal cortex ($\beta = -0.022$, $P_{corrected} = .035$) remained significant.

Associations Between PRS-SCZ and Cortical Volume

Analyses for the interaction between PRS-SCZ and hemisphere on global or regional CV did not demonstrate any significant effects (Supplementary Table S2). Similar to the results for surface area, PRS-SCZ was not associated with global CV ($\beta = -0.004$, $P_{corrected} = .323$; Supplementary Table S3; Figure 1C), but supramarginal cortex ($\beta = -0.016$, $P_{corrected} = .013$, $R^2 = 0.017\%$; Table 2) and superior temporal cortex ($\beta = -0.018$, $P_{corrected} < .001$, $R^2 = 0.015\%$). Analyses including only participants without self-reported mental illness found the same results (Supplementary Table S4).

Analyses in the subsample found associations with the supramarginal cortex, superior temporal cortex, and inferior frontal cortex (Supplementary Table S5). Among




Fig. 1. Cortical map of associations between the polygenic risk score for schizophrenia and (A) cortical thickness, (B) surface area and (C) cortical volume. Regions were mapped on the left hemisphere. Pink colours indicate positive associations and blue colours negative associations.

Table 3. The Association Between Polygenic Risk Score for Schizophrenia and Brain Structures, Adjusted for Childhood Trauma, Cannabis Use, Birth Weight, Winter/Spring Season of Birth, Townsend Deprivation Index and Excluding Participants Having used Antipsychotics

Brain Structure	N	β	SE	z	P	$P_{corrected}$
Surface Area						
Supramarginal	8638	-0.028	0.007	-3.93	<.001	<.001
Superior Temporal	8637	-0.021	0.007	-3.06	.002	.026
Inferior Frontal	8639	-0.022	0.008	-2.86	.004	.035
Cortical Volume						
Inferior Frontal	8635	-0.025	0.008	-3.29	.001	.026

them, inferior frontal cortex ($\beta = -0.026$, $P_{corrected} = .026$; Table 3) remained significant when environmental risk factors were added as covariates.

Associations Between PRS-SCZ and Subcortical Volumes

Analyses for the interaction between PRS-SCZ and hemisphere found a significant interaction effect for the hippocampus ($\beta = 0.011$, $P_{corrected} = .025$; Supplementary Table S2) and nucleus accumbens ($\beta = -0.015$, $P_{corrected} = .025$). Therefore, we also examined the left and right hippocampus and nucleus accumbens separately in the following analyses.

PRS-SCZ was associated with reduced volume in the right accumbens before ($\beta = -0.013$, $P_{uncorrected} = .043$; Supplementary Table S3), but not after FDR correction. Similarly, when environmental risk factors were taken into account, no subcortical structure survived correction for multiple comparisons (Supplementary Table S5).

PRS-SCZ and Environmental Risk Factors

We firstly tested gene by environment correlation using the linear regression model for each of the environmental factors. We found PRS-SCZ was significantly associated with Townsend deprivation index ($\beta = 0.015$, $t = 1.99$, $P = .047$), cannabis use ($\beta = 0.028$, $t = 3.28$, $P = .001$) and childhood trauma ($\beta = 0.060$, $t = 6.66$, $P < .001$), but not birth weight ($\beta = -0.006$, $t = -0.62$, $P = .535$).

For the interaction between PRS-SCZ and each risk factor, we found no statistically significant results, albeit some modest associations before FDR correction. For example, PRS-SCZ \times childhood trauma on SA in the medial orbitofrontal cortex ($\beta = -0.013$, $P_{uncorrected} = .013$; Supplementary Table S6): before FDR correction there was a negative association of PRS-SCZ with SA in the medial orbitofrontal cortex in participants exposed to more childhood trauma and a positive association in those who experienced less childhood trauma. More detailed results for the interaction effect are shown in Supplementary Tables S7–S11. Statistics for main

effects of the environmental factors are also provided (Supplementary Tables S12–S16).

Discussion

In this study, we have observed associations between an increased genetic liability for developing schizophrenia and wide-spread cortical differences in the general population, including lower CT in frontal lobe, insula lobe, lateral orbitofrontal cortex, medial orbitofrontal cortex, inferior frontal cortex, and posterior cingulate cortex, as well as reduced SA and CV in the supramarginal cortex and superior temporal cortex. In addition, the associations with reduced SA and CV remained after adjustment for environmental risk factors, indicating that some cortical differences might be driven predominantly by genetic liability for schizophrenia rather than environmental risk factors. Finally, our results suggest that PRS-SCZ and these environmental risk factors might contribute independently to brain abnormalities in schizophrenia.

PRS-SCZ and Cortical Thickness

Previous studies of the relationship between PRS-SCZ and global CT have been inconsistent, with global cortical thinning^{12,30} or no association⁵⁷ reported. Here, we found no association between PRS-SCZ and global CT, which is unsurprising because schizophrenia-associated genetic variants showed no significant enrichment in mean CT⁹. For regional measures, we replicated significant associations with reduced CT in insula, lateral orbitofrontal cortex, and inferior frontal gyrus, as reported in previous studies in UK Biobank.^{5,12,58} In addition, we observed reduced CT within the frontal lobe, medial orbitofrontal cortex, and posterior cingulate cortex. Reduced CT in these regions has been commonly observed in individuals with schizophrenia^{3,17,59–61} and in individuals at high genetic risk of schizophrenia.^{24,59,62} These regions may also be implicated in the symptoms seen in schizophrenia: the insula is engaged in auditory hallucinations⁵⁸; the orbitofrontal cortex is thought to play a role in negative symptoms⁶³; and the frontal lobe has shown associations with cognitive impairment in schizophrenia.⁶⁴

PRS-SCZ and Surface Area

We found that PRS-SCZ was not associated with global SA. Previous studies in this area have reported inconsistent findings.^{12,48,57} Analyses for regional SA found negative associations within temporal cortices: the supramarginal cortex and superior temporal cortex. This is in line with the significant enrichment of schizophrenia GWAS loci in SA of temporal regions.⁹ Previous studies support structural differences in superior temporal gyrus and inferior frontal cortex as possible biomarkers

in schizophrenia.^{65,66} Baseline gray matter reductions in superior temporal and inferior frontal areas are associated with later transition to psychosis.²¹ Additionally, correlations have been observed between superior temporal gyrus atrophy and positive psychotic symptoms, especially auditory verbal hallucinations.^{67–69} Similarly, the involvement of supramarginal and inferior frontal cortex in auditory hallucinations has been extensively documented⁷⁰ and the supramarginal gyrus is associated with delusions of reference and persecutory delusions.⁵⁸ Individual differences in these regions may represent general susceptibility to psychotic symptoms and vulnerability to developing schizophrenia.

PRS-SCZ and Cortical Volume

Previous findings relating to the relationship between PRS-SCZ and brain volume, have also been inconsistent. Terwisscha van Scheltinga et al.²⁵ found PRS-SCZ was significantly associated with smaller total brain volume regardless of disease status, but later studies found different results even within larger samples.^{12,26,71,72} We found no such association. However, we found significant volume reduction in supramarginal cortex and superior temporal cortex. When environmental risk factors were taken into account, an association of PRS-SCZ with lower inferior frontal cortex volume was significant, and associations with both supramarginal cortex and superior temporal cortex were nominally significant. As indicated earlier, this is in line with putative roles for these structures in processing auditory inputs, and their relation to auditory hallucinations in schizophrenia.^{66,73,74}

PRS-SCZ and Subcortical Volumes

Previous studies indicate heterogeneity of findings in subcortical volumes. Although smaller volumes of the pallidum⁴⁹ and thalamus⁴⁸ have been found to be associated with PRS-SCZ, others found no significant association.^{5,13,26,57,75} The largest study to date recently reported associations with smaller hippocampus and larger caudate and putamen volume.²⁸ These heterogeneous results may derive from differences in sample characteristics such as age, sample sizes, methods of calculating PRS-SCZ, as well as statistical models and covariates included. Here, we observed no association with the above subcortical volumes and a modest association with the right nucleus accumbens. Smaller nucleus accumbens has been reported in individuals with schizophrenia,^{4,5} as well as in their first-degree relatives.^{22,59} The nucleus accumbens is implicated in numerous neurological and psychiatric disorders, and is a main target of antipsychotic drugs and neurosurgical intervention in schizophrenia.^{76,77} However, it should be noted that the association with the right nucleus accumbens was no longer significant after

FDR correction. Further investigation is needed to disentangle the relationship between PRS-SCZ and subcortical volumes.

Influence of Environmental Risk Factors

When environmental risk factors were included in the model as covariates and participants on antipsychotic medication were excluded, we observed a similar pattern of gray matter reduction; the effects for the supramarginal cortex, superior temporal cortex, and inferior frontal cortex remained significant. Although these environmental risk factors seem to show little impact on brain structure, they are still important considerations. Marsman et al.⁷⁸ examined the relative contributions of genes and environment to mental health and found that familial and environmental factors explained around 17% of the variance, of which around 3% by PRS. Indeed, environmental risk factors, such as cannabis use, childhood trauma, and socioeconomic status, increase the risk for multidimensional symptoms in schizophrenia, including cognitive, affective, negative, and predominantly positive symptoms such as hallucinations and delusions^{79–82} and elevate the risk of developing schizophrenia.^{83,84} Moreover, these environmental risk factors exhibit associations with structural differences in widespread brain regions across frontal, parietal, temporal, and occipital cortex, as well as in subcortical volumes.^{46,85–87} We found evidence of main effects of environment risk factors on certain brain measures, although their associations with brain structures related to PRS-SCZ were weaker compared to those of PRS-SCZ. Future studies on brain abnormalities in schizophrenia should consider the role of environmental risks more closely.

Correlation Between PRS-SCZ and Environmental Risk Factors

We found that genetic risk for schizophrenia was associated with greater likelihood of using cannabis,^{88,89} experiencing more childhood trauma^{90,91} and higher socioeconomic deprivation, but was not associated with birth weight.¹² Previous studies on genetic influences on environmental measures demonstrate considerable heritability⁹² and GWASs have found many genetic variants associated with Townsend deprivation index,^{93,94} birth weight⁹⁵, and cannabis use.^{96,97} Other studies also reported genetic correlations between Townsend deprivation index, cannabis use, and schizophrenia.^{89,93,96} As a result, the associations we observed may be due to shared genetic aetiologies.

Interaction Between PRS-SCZ and Environmental Risk Factors

To our knowledge, only one study so far has reported significant interaction between PRS-SCZ and environmental

risk on brain structure: higher PRS-SCZ was associated with lower mean CT in male cannabis users, while there was no significant association in male non-users.⁴⁵ By contrast, studies focused on schizophrenia susceptibility genes especially *COMT* (catechol-O-methyltransferase) and *BDNF* (brain-derived neurotrophic factor) demonstrated interactions with obstetric complications, early life stress, and cannabis abuse,^{98,99} supporting the role of gene–environment interaction. Together with the modest interaction in this study, while preliminary, we recommend that further confirmatory studies in even larger clinical and non-clinical samples should be conducted to improve understanding of gene-environment interactions in schizophrenia.

Strengths and Limitations

This study has identified associations between PRS-SCZ and multiple brain measures in a large population-based sample. Nevertheless, it should be noted that the variance explained by PRS-SCZ alone is very small (maximum $R^2 \leq 0.02\%$). The use of PRS-SCZ and related biomarkers in clinical practice could be very limited, though it is a promising tool in the translation of genomic discovery to the clinic. In addition, we considered the influence of environmental risk factors for schizophrenia and explored gene-by-environment interactions, and found some weak associations and interactions. Further studies which take these variables into account will need to be undertaken with larger samples. Furthermore, our study was conducted in White British participants aged from 45 to 80, while the peak age for psychosis risk is 15–35.³⁹ Including White British participants only meant we were not able to examine the role of some socio-demographic and environmental factors for psychosis, especially those related to ethnicity.³⁹ Therefore, we should be very cautious about the generalization of our results to individuals from other backgrounds. Future research extending to diverse populations is warranted to understand the relationship between PRS-SCZ and brain structure. Finally, the environmental factors in this study were limited to childhood trauma, cannabis use, Townsend deprivation index, birth weight, and season of birth. To develop a fuller picture of gene-by-environment interactions, additional studies on other factors such as migration background³⁹ are required.

Conclusion

In summary, this study suggests that gray matter reductions in multiple regions, predominantly in frontal and temporal regions, are neuroanatomical correlates of increased genetic liability for schizophrenia. Further, environmental risk factors such as childhood trauma, cannabis use, Townsend deprivation index, birth weight, and season of birth, appear to contribute very little to

these associations, and genetic liability for schizophrenia and these environmental factors might contribute independently to brain abnormalities in schizophrenia. Our findings are meaningful in terms of identifying neuroimaging-based biomarkers for schizophrenia and elucidating the underlying genetic pathophysiology of schizophrenia.

Supplementary Material

Supplementary data are available at *Schizophrenia Bulletin Open* online.

Acknowledgments

We gratefully acknowledge all participants and researchers in UK Biobank who made the study possible.

Funding

XZ acknowledges financial support from China Scholarship Council. RJS is funded by a University of Glasgow Lord Kelvin/Adam Smith Fellowship and a UKRI Innovation-HDR-UK Fellowship (MR/S003061/1). DJS acknowledges support from a Lister Institute Prize Fellowship and an MRC Mental Health Data Pathfinder Award (MC_PC_17217). JW is funded by DJS Lister Institute Prize Fellowship. LML is supported by a Royal College of Physicians of Edinburgh JMAS Sim Fellowship. The authors declare that there is no conflict of interest.

References

1. Whiteford HA, Degenhardt L, Rehm J, *et al.* Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet*. 2013;382(9904):1575–1586.
2. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—an overview. *JAMA Psychiatry*. 2020;77(2):201–210.
3. van Erp TGM, Walton E, Hibar DP, *et al.*; Karolinska Schizophrenia Project. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. *Biol Psychiatry*. 2018;84(9):644–654.
4. van Erp TG, Hibar DP, Rasmussen JM, *et al.* Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol Psychiatry*. 2016;21(4):547–553.
5. Alnæs D, Kaufmann T, van der Meer D, *et al.*; Karolinska Schizophrenia Project Consortium. Brain heterogeneity in schizophrenia and its association with polygenic risk. *JAMA Psychiatry*. 2019;76(7):739–748.
6. Rimol LM, Nesvåg R, Hagler DJ Jr, *et al.* Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. *Biol Psychiatry*. 2012;71(6):552–560.
7. Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. *Nat Rev Neurosci*. 2017;18(12):727–740.

8. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421.
9. Lee PH, Baker JT, Holmes AJ, *et al*. Partitioning heritability analysis reveals a shared genetic basis of brain anatomy and schizophrenia. *Mol Psychiatry*. 2016;21(12):1680–1689.
10. Ruderfer DM, Ripke S, McQuillin A, *et al*. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. *Cell*. 2018;173(7):1705–1715. e1716.
11. Pardiñas AF, Holmans P, Pocklington AJ, *et al*; GERAD1 Consortium; CRESTAR Consortium. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet*. 2018;50(3):381–389.
12. Neilson E, Shen X, Cox SR, *et al*. Impact of polygenic risk for schizophrenia on cortical structure in UK biobank. *Biol Psychiatry*. 2019;86(7):536–544.
13. Grama S, Willcocks I, Hubert JJ, *et al*. Polygenic risk for schizophrenia and subcortical brain anatomy in the UK Biobank cohort. *Transl Psychiatry*. 2020;10(1):309.
14. Murray RM, Vassos E. Nature, nurture, and the polygenic risk score for schizophrenia. *Schizophr Bull*. 2020;46(6):1363–1365.
15. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. *Schizophr Bull*. 2013;39(5):1129–1138.
16. Takayanagi Y, Sasabayashi D, Takahashi T, *et al*. Reduced cortical thickness in schizophrenia and schizotypal disorder. *Schizophr Bull*. 2020;46(2):387–394.
17. Madre M, Canales-Rodríguez EJ, Fuentes-Claramonte P, *et al*. Structural abnormality in schizophrenia versus bipolar disorder: a whole brain cortical thickness, surface area, volume and gyrification analyses. *Neuroimage Clin*. 2020;25:102131.
18. Takahashi T, Suzuki M. Brain morphologic changes in early stages of psychosis: implications for clinical application and early intervention. *Psychiatry Clin Neurosci*. 2018;72(8):556–571.
19. Dietsche B, Kircher T, Falkenberg I. Structural brain changes in schizophrenia at different stages of the illness: a selective review of longitudinal magnetic resonance imaging studies. *Aust N Z J Psychiatry*. 2017;51(5):500–508.
20. Sugranyes G, de la Serna E, Ilzarbe D, *et al*. Brain structural trajectories in youth at familial risk for schizophrenia or bipolar disorder according to development of psychosis spectrum symptoms. *J Child Psychol Psychiatry*. 2021;62(6):780–789.
21. Fusar-Poli P, Borgwardt S, Crescini A, *et al*. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. *Neurosci Biobehav Rev*. 2011;35(5):1175–1185.
22. de Zwarte SMC, Brouwer RM, Agartz I, *et al*. The association between familial risk and brain abnormalities is disease specific: an ENIGMA-relatives study of schizophrenia and bipolar disorder. *Biol Psychiatry*. 2019;86(7):545–556.
23. Zhang W, Sweeney JA, Yao L, *et al*. Brain structural correlates of familial risk for mental illness: a meta-analysis of voxel-based morphometry studies in relatives of patients with psychotic or mood disorders. *Neuropsychopharmacology*. 2020;45(8):1369–1379.
24. de Zwarte SMC, Brouwer RM, Agartz I, *et al*. Intelligence, educational attainment, and brain structure in those at familial high-risk for schizophrenia or bipolar disorder. *Hum Brain Mapp*. 2020:1–17.
25. Terwisscha van Scheltinga AF, Bakker SC, van Haren NE, *et al*; Psychiatric Genome-wide Association Study Consortium. Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. *Biol Psychiatry*. 2013;73(6):525–531.
26. Reus LM, Shen X, Gibson J, *et al*. Association of polygenic risk for major psychiatric illness with subcortical volumes and white matter integrity in UK Biobank. *Sci Rep*. 2017;7:42140.
27. van der Merwe C, Passchier R, Mufford M, Ramesar R, Dalvie S, Stein DJ. Polygenic risk for schizophrenia and associated brain structural changes: A systematic review. *Compr Psychiatry*. 2019;88:77–82.
28. Stauffer E-M, Bethlehem RAI, Warriar V, *et al*. Grey and white matter microstructure is associated with polygenic risk for schizophrenia. *Mol Psychiatry*. 2021. doi:10.1038/s41380-021-01260-5
29. Harris MA, Shen X, Cox SR, *et al*. Stratifying major depressive disorder by polygenic risk for schizophrenia in relation to structural brain measures. *Psychol Med*. 2020;50(10):1653–1662.
30. Neilson E, Bois C, Gibson J, *et al*. Effects of environmental risks and polygenic loading for schizophrenia on cortical thickness. *Schizophr Res*. 2017;184:128–136.
31. De Peri L, Vita A. Factors associated with brain heterogeneity in schizophrenia. *JAMA Psychiatry*. 2019;76(11):1210–1211.
32. van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. *Schizophr Bull*. 2008;34(6):1066–1082.
33. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. *Lancet*. 2014;383(9929):1677–1687.
34. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. *Nature*. 2010;468(7321):203–212.
35. Agerbo E, Sullivan PF, Vilhjálmsson BJ, *et al*. Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: a danish population-based study and meta-analysis. *JAMA Psychiatry*. 2015;72(7):635–641.
36. Stepniak B, Papiol S, Hammer C, *et al*. Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study. *Lancet Psychiatry*. 2014;1(6):444–453.
37. Schmitt A, Malchow B, Hasan A, Falkai P. The impact of environmental factors in severe psychiatric disorders. *Front Neurosci*. 2014;8:19.
38. Belbasis L, Köhler CA, Stefanis N, *et al*. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. *Acta Psychiatr Scand*. 2018;137(2):88–97.
39. Radua J, Ramella-Cravaro V, Ioannidis JPA, *et al*. What causes psychosis? An umbrella review of risk and protective factors. *World Psychiatry*. 2018;17(1):49–66.
40. Guloksuz S, Pries LK, Delespaul P, *et al*; Genetic Risk and Outcome of Psychosis (GROUP) investigators. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. *World Psychiatry*. 2019;18(2):173–182.
41. Liuhanen J, Suvisaari J, Kajantie E, *et al*. Interaction between compound genetic risk for schizophrenia and high birth weight contributes to social anhedonia and schizophrenia in women. *Psychiatry Res*. 2018;259:148–153.

42. Trotta A, Iyegbe C, Di Forti M, *et al.* Interplay between schizophrenia polygenic risk score and childhood adversity in first-presentation psychotic disorder: a pilot study. *PLoS One*. 2016;11(9):e0163319.
43. Lee SH, Byrne EM, Hultman CM, *et al.*; Schizophrenia Working Group of the Psychiatric Genomics Consortium and Rheumatoid Arthritis Consortium International; Schizophrenia Working Group of the Psychiatric Genomics Consortium Authors; Schizophrenia Working Group of the Psychiatric Genomics Consortium Collaborators; Rheumatoid Arthritis Consortium International Authors; Rheumatoid Arthritis Consortium International Collaborators. New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. *Int J Epidemiol*. 2015;44(5):1706–1721.
44. Cancel A, Dallel S, Zine A, El-Hage W, Fakra E. Understanding the link between childhood trauma and schizophrenia: A systematic review of neuroimaging studies. *Neurosci Biobehav Rev*. 2019;107:492–504.
45. French L, Gray C, Leonard G, *et al.* Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. *JAMA Psychiatry*. 2015;72(10):1002–1011.
46. Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J; Genetic Risk and Outcome of Psychosis (G.R.O.U.P). Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. *Biol Psychiatry*. 2011;69(5):487–494.
47. Cancel A, Comte M, Truillet R, *et al.* Childhood neglect predicts disorganization in schizophrenia through grey matter decrease in dorsolateral prefrontal cortex. *Acta Psychiatr Scand*. 2015;132(4):244–256.
48. Córdova-Palomera A, Kaufmann T, Bettella F, *et al.* Effects of autozygosity and schizophrenia polygenic risk on cognitive and brain developmental trajectories. *Eur J Hum Genet*. 2018;26(7):1049–1059.
49. Caseras X, Tansey KE, Foley S, Linden D. Association between genetic risk scoring for schizophrenia and bipolar disorder with regional subcortical volumes. *Transl Psychiatry*. 2015;5:e692.
50. Desikan RS, Ségonne F, Fischl B, *et al.* An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*. 2006;31(3):968–980.
51. Vilhjálmsson BJ, Yang J, Finucane HK, *et al.*; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) study. Modeling linkage disequilibrium increases accuracy of polygenic risk scores. *Am J Hum Genet*. 2015;97(4):576–592.
52. Miller KL, Alfaro-Almagro F, Bangerter NK, *et al.* Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Nat Neurosci*. 2016;19(11):1523–1536.
53. Glaesmer H, Schulz A, Häuser W, Freyberger HJ, Brähler E, Grabe H-J. The childhood trauma screener (CTS)-development and validation of cut-off-scores for classificatory diagnostics. *Psychiatr Prax*. 2013;40(4):220–226.
54. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol*. 1995;57(1):289–300.
55. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. *Neurosci Biobehav Rev*. 2013;37(8):1680–1691.
56. Lesh TA, Tanase C, Geib BR, *et al.* A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. *JAMA Psychiatry*. 2015;72(3):226–234.
57. Lancaster TM, Dimitriadis SL, Tansey KE, *et al.* Structural and functional neuroimaging of polygenic risk for schizophrenia: a recall-by-genotype-based approach. *Schizophr Bull*. 2019;45(2):405–414.
58. Alloza C, Blesa-Cábez M, Bastin ME, *et al.* Psychotic-like experiences, polygenic risk scores for schizophrenia, and structural properties of the salience, default mode, and central-executive networks in healthy participants from UK Biobank. *Transl Psychiatry*. 2020;10(1):122.
59. de Zwarte SMC, Brouwer RM, Tsouli A, *et al.* Running in the family? Structural brain abnormalities and IQ in offspring, siblings, parents, and co-twins of patients with schizophrenia. *Schizophr Bull*. 2019;45(6):1209–1217.
60. Wannan CMJ, Cropley VL, Chakravarty MM, *et al.* Evidence for network-based cortical thickness reductions in schizophrenia. *Am J Psychiatry*. 2019;176(7):552–563.
61. Shahab S, Mulsant BH, Levesque ML, *et al.* Brain structure, cognition, and brain age in schizophrenia, bipolar disorder, and healthy controls. *Neuropsychopharmacology*. 2019;44(5):898–906.
62. Byun MS, Kim JS, Jung WH, *et al.* Regional cortical thinning in subjects with high genetic loading for schizophrenia. *Schizophr Res*. 2012;141(2-3):197–203.
63. Kanahara N, Sekine Y, Haraguchi T, *et al.* Orbitofrontal cortex abnormality and deficit schizophrenia. *Schizophr Res*. 2013;143(2-3):246–252.
64. Jirsaraie RJ, Sheffield JM, Barch DM. Neural correlates of global and specific cognitive deficits in schizophrenia. *Schizophr Res*. 2018;201:237–242.
65. Bandeira ID, Barouh JL, Bandeira ID, Quarantini L. Analysis of the superior temporal gyrus as a possible biomarker in schizophrenia using voxel-based morphometry of the brain magnetic resonance imaging: a comprehensive review. *CNS Spectr*. 2020;10:1–7.
66. Knöchel C, Stäblein M, Prvulovic D, *et al.* Shared and distinct gray matter abnormalities in schizophrenia, schizophrenia relatives and bipolar disorder in association with cognitive impairment. *Schizophr Res*. 2016;171(1–3):140–148.
67. Köse G, Jessen K, Ebdrup BH, Nielsen MØ. Associations between cortical thickness and auditory verbal hallucinations in patients with schizophrenia: a systematic review. *Psychiatry Res Neuroimaging*. 2018;282:31–39.
68. van Tol MJ, van der Meer L, Bruggeman R, Modinos G, Knegtering H, Aleman A. Voxel-based gray and white matter morphometry correlates of hallucinations in schizophrenia: The superior temporal gyrus does not stand alone. *Neuroimage Clin*. 2014;4:249–257.
69. Walton E, Hibar DP, van Erp TG, *et al.*; Karolinska Schizophrenia Project Consortium (KaSP). Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium. *Acta Psychiatr Scand*. 2017;135(5):439–447.
70. Gaser C, Nenadic I, Volz HP, Büchel C, Sauer H. Neuroanatomy of “hearing voices”: a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. *Cereb Cortex*. 2004;14(1):91–96.

71. Papiol S, Mitjans M, Assogna F, *et al.* Polygenic determinants of white matter volume derived from GWAS lack reproducibility in a replicate sample. *Transl Psychiatry*. 2014;4:e362.
72. Van der Auwera S, Wittfeld K, Homuth G, Teumer A, Hegenscheid K, Grabe HJ. No association between polygenic risk for schizophrenia and brain volume in the general population. *Biol Psychiatry*. 2015;78(11):e41–e42.
73. Oberhuber M, Hope TMH, Seghier ML, *et al.* Four functionally distinct regions in the left supramarginal gyrus support word processing. *Cereb Cortex*. 2016;26(11):4212–4226.
74. Nenadic I, Smesny S, Schlösser RG, Sauer H, Gaser C. Auditory hallucinations and brain structure in schizophrenia: voxel-based morphometric study. *Br J Psychiatry*. 2010;196(5):412–413.
75. Franke B, Stein JL, Ripke S, *et al.*; Schizophrenia Working Group of the Psychiatric Genomics Consortium; ENIGMA Consortium. Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. *Nat Neurosci*. 2016;19(3):420–431.
76. Perez SM, Lodge DJ. Convergent inputs from the hippocampus and thalamus to the nucleus accumbens regulate dopamine neuron activity. *J Neurosci*. 2018;38(50):10607–10618.
77. Salgado S, Kaplitt MG. The nucleus accumbens: a comprehensive review. *Stereotact Funct Neurosurg*. 2015;93(2):75–93.
78. Marsman A, Pries LK, Ten Have M, *et al.* Do current measures of polygenic risk for mental disorders contribute to population variance in mental health? *Schizophr Bull*. 2020;46(6):1353–1362.
79. Gallagher BJ 3rd, Jones BJ. Early-onset schizophrenia: symptoms and social class of origin. *Int J Soc Psychiatry*. 2017;63(6):492–497.
80. Smeets F, Lataster T, Viechtbauer W, Delespaul P; G.R.O.U.P. Evidence that environmental and genetic risks for psychotic disorder may operate by impacting on connections between core symptoms of perceptual alteration and delusional ideation. *Schizophr Bull*. 2015;41(3):687–697.
81. Dauvermann MR, Donohoe G. The role of childhood trauma in cognitive performance in schizophrenia and bipolar disorder - a systematic review. *Schizophr Res Cogn*. 2019;16:1–11.
82. Torniainen M, Wegelius A, Tuulio-Henriksson A, Lönnqvist J, Suvisaari J. Both low birthweight and high birthweight are associated with cognitive impairment in persons with schizophrenia and their first-degree relatives. *Psychol Med*. 2013;43(11):2361–2367.
83. Welch KA, McIntosh AM, Job DE, *et al.* The impact of substance use on brain structure in people at high risk of developing schizophrenia. *Schizophr Bull*. 2011;37(5):1066–1076.
84. Luo Y, Zhang L, He P, Pang L, Guo C, Zheng X. Individual-level and area-level socioeconomic status (SES) and schizophrenia: cross-sectional analyses using the evidence from 1.9 million Chinese adults. *BMJ Open*. 2019;9(9):e026532.
85. Abush H, Ghose S, Van Enkevort EA, *et al.* Associations between adolescent cannabis use and brain structure in psychosis. *Psychiatry Res Neuroimaging*. 2018;276:53–64.
86. Farah MJ. The neuroscience of socioeconomic status: correlates, causes, and consequences. *Neuron*. 2017;96(1):56–71.
87. Paquola C, Bennett MR, Lagopoulos J. Understanding heterogeneity in grey matter research of adults with childhood maltreatment—a meta-analysis and review. *Neurosci Biobehav Rev*. 2016;69:299–312.
88. Power RA, Verweij KJ, Zuhair M, *et al.* Genetic predisposition to schizophrenia associated with increased use of cannabis. *Mol Psychiatry*. 2014;19(11):1201–1204.
89. Verweij KJ, Abdellaoui A, Nivard MG, *et al.*; International Cannabis Consortium. Short communication: genetic association between schizophrenia and cannabis use. *Drug Alcohol Depend*. 2017;171:117–121.
90. Sallis HM, Croft J, Havdahl A, *et al.* Genetic liability to schizophrenia is associated with exposure to traumatic events in childhood. *Psychol Med*. 2020;51(11):1814–1821.
91. Veling W, Counotte J, Pot-Kolder R, van Os J, van der Gaag M. Childhood trauma, psychosis liability and social stress reactivity: a virtual reality study. *Psychol Med*. 2016;46(16):3339–3348.
92. Kendler KS, Baker JH. Genetic influences on measures of the environment: a systematic review. *Psychol Med*. 2007;37(5):615–626.
93. Hill WD, Hagenaars SP, Marioni RE, *et al.* Molecular genetic contributions to social deprivation and household income in UK Biobank. *Curr Biol*. 2016;26(22):3083–3089.
94. Marioni RE, Davies G, Hayward C, *et al.* Molecular genetic contributions to socioeconomic status and intelligence. *Intelligence*. 2014;44(100):26–32.
95. Horikoshi M, Beaumont RN, Day FR, *et al.*; CHARGE Consortium Hematology Working Group; Early Growth Genetics (EGG) Consortium. Genome-wide associations for birth weight and correlations with adult disease. *Nature*. 2016;538(7624):248–252.
96. Pasmán JA, Verweij KJH, Gerring Z, *et al.*; 23andMe Research Team; Substance Use Disorders Working Group of the Psychiatric Genomics Consortium; International Cannabis Consortium. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. *Nat Neurosci*. 2018;21(9):1161–1170.
97. Stringer S, Minică CC, Verweij KJ, *et al.* Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. *Transl Psychiatry*. 2016;6:e769.
98. Misiak B, Stramecki F, Gawęda Ł, *et al.* Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: a systematic review. *Mol Neurobiol*. 2018;55(6):5075–5100.
99. Geoffroy PA, Etain B, Houenou J. Gene x environment interactions in schizophrenia and bipolar disorder: evidence from neuroimaging. *Front Psychiatry*. 2013;4:136.